An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Latest Information Update: 17 Jun 2022
Price :
$35 *
At a glance
- Drugs Itacitinib (Primary) ; Ruxolitinib
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Therapeutic Use
- Sponsors Incyte Corporation
- 06 Jul 2021 Status changed from active, no longer recruiting to completed.
- 11 Jun 2021 Planned End Date changed from 31 Mar 2021 to 29 Jun 2021.
- 25 Jan 2021 Planned End Date changed from 31 Dec 2020 to 31 Mar 2021.